France· FR:60823764
LUTATHERA 370 MBq/ml, solution pour perfusion
A medicinal product containing lutécium (177lu) oxodotréotide, registered in France by NOVARTIS EUROPHARM (IRLANDE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- LUTÉCIUM (177LU) OXODOTRÉOTIDE
- Manufacturer
- NOVARTIS EUROPHARM (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550443381 flacon(s) en verre de 20,5 Ã 25,0 mL de solution
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d024f14f-e032-4ce7-9616-ba0c8ad134fb GET /v1/drugs/d024f14f-e032-4ce7-9616-ba0c8ad134fb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "60823764",
"date_amm": "2017-09-26",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/17/1226",
"substance": "LUTÉCIUM (177LU) OXODOTRÉOTIDE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about lutécium (177lu) oxodotréotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.